antibody–drug conjugates

Metastatic metaplastic triple negative breast cancer response to sacituzumab govitecan and biomarker targetability

Maheswaran S, Dedeoglu AS, Niemierko A, Abelman RO, Jimenez R, Rieur O, Hutchinson J, Vidula N, Spring LM, Ellisen LW, Isakoff SJ, Wander SA, Bardia[...]

By sjmartinez • October 2, 2026

TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy

Bardia A, Pusztai L, Albain K, Ciruelos EM, Im SA, Hershman D, Kalinsky K, Isaacs C, Loirat D, Testa L, Tokunaga E, Wu J, Dry[...]

By sjmartinez • April 30, 2024